Dr. Mustapha Ahmad Ezzeddine, MD

Dr. Ezzeddine practices at Davie Surgery - Ophthalmology - HOPD in Bermuda Run, North Carolina.

Dr. Ezzeddine's NPI, 1972534667, was assigned on July 5, 2006. Dr. Ezzeddine holds North Carolina license 2019-02683.

Dr. Ezzeddine's primary practice is Davie Surgery - Ophthalmology - HOPD, at 329 Nc Highway 801 N, Bermuda Run, NC 27006.

Dr. Ezzeddine's primary practice is Davie Surgery - Ophthalmology - HOPD in Bermuda Run, North Carolina. Dr. Ezzeddine is also affiliated with Atrium Health Wake Forest Baptist Medical Center. The medical group on file is Atrium Health Wake Forest Baptist.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ezzeddine practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Ezzeddine's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dmand AI has Dr. Ezzeddine's licenses on file in 2 states: North Carolina and Minnesota.

CMS data shows 64 Medicare services from Dr. Ezzeddine across 3 procedure codes in 2024, for 59 Medicare patients. Medicare paid $5,640 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 59 Medicare patients who saw Dr. Ezzeddine in 2024. The largest group is 75 to 84, with 22 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ezzeddine's median patient age at 72, with 60% women.

In 2024, Dr. Ezzeddine wrote 32 Medicare Part D claims for 15 patients. 91% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $99,532 in total drug cost. In 2018, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Ezzeddine for performance year 2024, reported as part of a group. Dr. Ezzeddine accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ezzeddine as offering telehealth.

Dmand AI links 23 papers to Dr. Ezzeddine, published from 2010 to 2021. 2012 was the busiest year, with 4. The most frequent topics are Stroke, Antihypertensive Agents and Blood Glucose. Dr. Ezzeddine has published most often in J Stroke Cerebrovasc Dis. Dr. Ezzeddine's most frequent co-authors are Gustavo Rodriguez, MD, Muhammad A. K. Suri, MD and Haralabos Zacharatos, DO.

Dmand AI links Dr. Ezzeddine to 4 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Hyperglycemia, Carotid Stenosis and Ischemic Attack, Transient.

CMS Open Payments shows 1 general payment to Dr. Ezzeddine from 1 drug or device company in 2016. Food and beverage make up the largest share, 100% of the total. Penumbra, Inc. paid the most, $119.